Publication date: Feb 03, 2026
Skyhawk Therapeutics has announced positive interim results from its phase 1 trial of SKY-0515, an investigational treatment for Huntingtons disease. The phase 1 clinical trial of SKY-0515 showed that patients receiving SKY-0515 had a mean Composite Unified Huntingtons Disease Rating Scale (cUHDRS) improvement from baseline of 0. 64 points at nine months of treatment, where a worsening of 0. 73 point .. .
| Concepts | Keywords |
|---|---|
| Fatal | Announced |
| Huntingtons | Approved |
| Professor | Clinical |
| Skyhawk | Disease |
| Dose | |
| Huntingtons | |
| Interim | |
| Phase | |
| Positive | |
| Sky | |
| Skyhawk | |
| Small | |
| Therapeutics | |
| Treatment | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Huntington’s disease |
| disease | MESH | neurodegenerative disorder |
Original Article
(Visited 14 times, 1 visits today)